Skyai, Inc. quarterly report, Q2 FY2024

Business Context and Reporting Period

Company: Sharps Technology, Inc. (STSS)

Filing Type: Form 10-Q (Unaudited)

Reporting Period: Quarter and six months ended June 30, 2024

Business Overview: Sharps is a pre-revenue medical device company focused on the design, patenting, and commercialization of safety syringes. The company operates a manufacturing facility in Hungary and maintains a corporate office in New York. As of the reporting date, the company has not generated significant revenue from product sales, though it reported its first sale of approximately $10,871 in the second quarter of 2024.

Key Financial Metrics

Metric Q2 2024 (3 Months) YTD 2024 (6 Months) YTD 2023 (6 Months)
Revenue $0 $0 $0
Net Loss $(2,102,327) $(3,084,713) $(4,717,655)
Operating Expenses $1,921,100 $3,765,152 $4,850,135
Cash Balance (End of Period) $1,483,293 $1,483,293 $2,924,019
Working Capital $978,400 $978,400 $1,145,569
Warrant Liability $1,443,662 $1,443,662 $2,422,785
Accumulated Deficit $(28,233,717) $(28,233,717) $(20,025,021)

Cash Flow (Six Months Ended June 30, 2024):

  • Operating Activities: Net cash used of $3,528,676.
  • Investing Activities: Net cash used of $1,019,355 (includes $1M forfeited escrow deposit).
  • Financing Activities: Net cash provided of $2,972,348 (from Reg A offering and warrant inducements).

Material Changes vs. Prior Period

  • Net Loss Reduction: Net loss for the six months ended June 30, 2024, decreased by approximately 35% compared to the same period in 2023, primarily due to a significant fair value gain on warrant liabilities ($1.67M) and reduced operating expenses.
  • Operating Expenses: Total operating expenses decreased by approximately 22% year-over-year. General and Administrative (G&A) expenses dropped by $904,570, driven by lower stock-based compensation, reduced public company costs, and the absence of a $375,000 contract settlement expense incurred in 2023.
  • Derivative Gains: The company recorded a fair value gain of $1.67M on warrant liabilities for the six months ended June 30, 2024, compared to a gain of $93,977 in the prior year period. This non-cash gain significantly offset operating losses.
  • Capital Structure: The company raised approximately $3.5M in gross proceeds during the second quarter of 2024 through a Reg A offering and warrant inducement exercises, increasing outstanding common shares from ~15.3M to ~28.6M.

Outlook, Risks, and Contingencies

Going Concern

Management has raised substantial doubt regarding the company's ability to continue as a going concern. With working capital of $978,400, the company states this is insufficient to fund planned operations for the next 12 months. Continued operations depend on raising additional financing through equity sales or debt.

Listing Status

The company failed to regain compliance with Nasdaq Listing Rule 5550(a)(2) (minimum bid price of $1.00) by the July 8, 2024 deadline. A hearing was requested, and trading remains suspended pending the hearing outcome on August 13, 2024. Stockholders approved a reverse stock split (up to 1-for-8) to address this issue.

Business Developments

  • Asset Purchase: A $1M escrow deposit for a potential $35M asset purchase from InjectEZ, LLC was forfeited in July 2024 as the transaction was not consummated by the deadline. Negotiations for an amended agreement are ongoing.
  • Supply Agreement: On July 24, 2024, the company entered into a five-year supply agreement with Stericare Solutions for 520 million units of syringes, with expected revenues exceeding $50M. Commencement is targeted for November 1, 2024.
  • Distribution: The company terminated its distribution agreement with Nephron Pharmaceuticals and entered into a new agreement with Roncadelle Operations for exclusive distribution in specific global regions.

Investor Verification Checklist

  • Going Concern Status: Verify the company's ability to secure additional funding to cover the projected cash burn rate, given the explicit "substantial doubt" disclosure.
  • Nasdaq Delisting Risk: Monitor the outcome of the August 13, 2024, hearing regarding the minimum bid price deficiency and the potential implementation of a reverse stock split.
  • Revenue Recognition: Confirm the timing and volume of the first commercial orders under the new Stericare Solutions supply agreement, as the company remains pre-revenue.
  • Warrant Liability Volatility: Assess the impact of fair value adjustments on warrant liabilities, which caused a $1.67M non-cash gain this period but could result in significant non-cash losses in future periods if stock prices or volatility change.
  • Asset Acquisition Contingency: Review the status of the amended Asset Purchase Agreement with InjectEZ, LLC, following the forfeiture of the $1M deposit.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.